Progress of solute carrier SLC family in nonalcoholic fatty liver disease.

Nonalcoholic fatty liver disease is closely related to obesity and type 2 diabetes mellitus, and is one of the components of metabolic syndrome. Due to the complexity of its pathogenesis, there is no effective drug treatment to date. Solute carrier transporters are associated with a variety of metabolic diseases and are abundantly expressed in the liver. They participate in the transport of a variety of nutrients and metabolites, regulate nutrient supply, metabolic transformation, energy balance and oxidative stress, and modulate the physiological functions of liver. Particularly, it is important that some of these SLC transporters have become new targets for drug development. In this review, we summarize the role of SLC in the transport of nutrients and liver metabolites and its correlation with NAFLD, and reveal the potential of SLC as a target for the development of new drugs for NAFLD treatment so as to provide a new choice for the treatment of the disease.非酒精性脂肪肝病(non-alcoholic fatty liver disease,NAFLD)与肥胖症和2型糖尿病密切相关,是代谢综合征的组成部分之一。由于NAFLD发病机制的复杂性,目前尚无针对性的药物治疗。溶质载体(solute carrier,SLC)转运蛋白与多种代谢性疾病有关,在肝脏中具有丰富表达,参与多种营养物质和代谢产物的转运,调节营养供应、代谢转换、能量平衡和氧化应激等,调控肝脏生理功能。尤为重要的是,其中部分SLC转运体已经成为药物开发的新靶标。本文重点阐述SLC在营养物质和肝脏代谢产物转运中的作用及其与NAFLD的相关性,并揭示SLC作为NAFLD新药研发潜在靶标的可能性,以期为治疗NAFLD提供新的选择。.